Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Novimmune SA currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is distributed across 2 distinct examiners and 2 distinct art units, indicating a spread of technical review for the portfolio. The presence of 2 distinct art units suggests that the company's biotech innovations are being evaluated under different examination frameworks. This structural variety requires counsel to monitor distinct procedural trends across different sections of the patent office while managing the 2 pending office actions.
The busiest examiner for this portfolio is KAUFMAN, CLAIRE M, who is responsible for 1 busiest_examiner_pending action. Because the total number of pending actions is 2 and the busiest examiner handles 1, the workload is divided between the 2 distinct examiners involved. Practitioners should note that this distribution prevents any single examiner from having a dominant influence over the current pending portfolio, requiring tailored strategies for each individual's preferences. Managing the workload across 2 distinct examiners means that each active file is currently being handled by a different person, necessitating a broad approach to examiner interviews and negotiation tactics in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KAUFMAN, CLAIRE M | 1 | 63.5% | +50.7% |
| BORGEEST, CHRISTINA M | 1 | 55.6% | +21.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18491130 | PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION | KAUFMAN, CLAIRE M | — |
| 18158980 | COMPOSITION AND METHODS FOR THE SELECTIVE ACTIVATION OF CYTOKINE SIGNALING PATHWAYS | BORGEEST, CHRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18491130 | PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION | KAUFMAN, CLAIRE M | 1674 | §103§112DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18158980 | COMPOSITION AND METHODS FOR THE SELECTIVE ACTIVATION OF CYTOKINE SIGNALING PATHWAYS | BORGEEST, CHRISTINA M | 1675 | §112 | Non-Final OA | — | Pending | Jan 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial